The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Phase 2

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Phase 2 · 40 people · 1 site in China · Recruiting now

October 20, 2026
A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases

Phase 2 · 25 people · 1 site in China · Recruiting now

October 20, 2026
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Phase 2 · 60 people · 1 site in China · Recruiting now

October 20, 2026
HTL0039732 in Participants With Advanced Solid Tumours

Phase 2 · 150 people · 6 sites in United Kingdom · Recruiting now

October 13, 2026
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Phase 2 · 35 people · 1 site in China · Recruiting now

October 13, 2026
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Phase 2 · 40 people · 5 sites in United States · Recruiting now

October 13, 2026
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Phase 2 · randomised · 60 people · 1 site in Italy · Recruiting now

October 13, 2026
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Phase 2 · randomised · 57 people · 1 site in United States · Recruiting now

October 13, 2026
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Phase 2 · randomised · 130 people · 3 sites in China · Recruiting now

October 13, 2026
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

Phase 2 · 23 people · 1 site in China · Recruiting now

September 29, 2026